Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

PURPOSE: One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (Alliance), a 2 × 2 factorial, open-label, randomized phase II trial, evaluated the impact of adding carboplatin and/or bevac...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Sikov, William M., Berry, Donald A., Perou, Charles M., Singh, Baljit, Cirrincione, Constance T., Tolaney, Sara M., Kuzma, Charles S., Pluard, Timothy J., Somlo, George, Port, Elisa R., Golshan, Mehra, Bellon, Jennifer R., Collyar, Deborah, Hahn, Olwen M., Carey, Lisa A., Hudis, Clifford A., Winer, Eric P.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2015
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4268249/
https://ncbi.nlm.nih.gov/pubmed/25092775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.0572
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items